17 July 2016

PRESS RELEASE – OREGA strengthens its intellectual property in Europe
17 July 2016

Press release OREGA Biotech strengthens its intellectual property OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification from the European Patent Office (EPO) stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers any antibody binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. This notification shortly follows another notice of allowance from the EPO which is about to deliver another strategic patent application held by INSERM and licensed to OREGA Biotech relating to antibodies that bind CD39. As of today, the patent portfolio of the company is composed of 8 families of patent applications owned or co-owned by OREGA biotech and one licensed patent. Read the press release.
[ Read more ]
17 April 2016

PRESS RELEASE – First-in-class CD39 Checkpoint Inhibitor presented 2016 AACR meeting
17 April 2016

Press release First-in-class CD39 Checkpoint Inhibitor presented at the AACR meeting Marseille and Lyon, April 19, 2016 – Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program, at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana, USA. Poster #3222 presents IPH52, Innate’s humanized anti-CD39 blocking antibody. This novel antibody exhibits high affinity and specificity for CD39 and potently inhibits ATPase activity in in vitro assays and ex vivo models with patient biopsies. In a murine tumor model, treatment with anti-CD39 antibody results in a significant decrease in tumor volume, and improved survival. Poster #3218 presents for the first time the impact of CD39 disruption on the efficacy of other cancer therapeutics by comparing their effects in wildtype versus CD39 knock-out mice. The results revealed that CD39 deficiency sensitized to anti-PD1 treatment in animals that failed to respond to anti-PD-1 treatment. The antitumor efficacy of CD39 disruption is further improved when combined with an immunogenic chemotherapy. In animals bearing PD-1 insensitive tumors, combination of immunogenic chemotherapy, anti-PD1 antibody and CD39 disruption led to complete tumor eradication and long term protection (specific anti-tumor immunity) in most animals. The efficacy of an ADCC-inducing cytotoxic antibody was also improved in CD39 knock-out mice compared to wildtype. Nicolai Wagtmann, CSO of Innate Pharma, said: “Taken together, the data presented by Innate and our partner OREGA Biotech form a very promising body of evidence supporting the development of this new, first-in-class checkpoint inhibitor antibody. The results presented today raise exciting perspectives for the development of IPH52, both as single-agent and in combination with other checkpoint inhibitors, and we are eager to now take this first-in-class candidate forward into the preclinical development phases”. Jeremy Bastid, COO of OREGA Biotech, further commented: “CD39 mediates immunosuppression through a different mechanism than other immune checkpoints and may broadly impede the efficacy of cancer therapies. The exciting data released today using both antibody blockade and genetic CD39 deficiency shed light on the capacity of CD39 disruption to drive antitumor immune responses, either alone or in combination with PD-1 checkpoint blockers, ADCC antibodies and immunogenic chemotherapy, suggesting broad development potential”. For more information, read the press release.
[ Read more ]
17 January 2016

PRESS RELEASE – OREGA announces licensing of CD39 Program to Innate Pharma
17 January 2016

Press Release Lyon, France, January 10th, 2016 OREGA Biotech announces Licensing Agreement with Innate Pharma OREGA Biotech today announces that it has entered into an exclusive licensing agreement with Innate Pharma by which OREGA grants Innate full worldwide rights to its program of first-in-class anti-CD39 immune checkpoint inhibitors. This license agreement arose from a fruitful research collaboration between the two companies initiated in 2014. Under the terms of the agreement, OREGA Biotech will receive undisclosed upfront payment, milestone payments for preclinical, clinical and regulatory achievements as well as royalties on net sales. For more information, read the press release.
[ Read more ]